Floatz Rating
B63/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06975644CT.gov Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC) | — | Not Yet Recruiting | — | — | — |
NCT06825455CT.gov Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06773091CT.gov A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06237881CT.gov A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06241456CT.gov FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05972720CT.gov A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma | — | Terminated | — | — | — |
NCT06302062CT.gov Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05881525CT.gov NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05275777CT.gov A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05279300CT.gov A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | — | Recruiting | — | — | — |
Show 22 more trialsShow fewer
NCT04146298CT.gov Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer | — | Recruiting | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04172259CT.gov ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | — | Active Not Recruiting | — | — | — |
NCT03610490CT.gov Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | — | Terminated | — | — | — |
NCT03449108CT.gov LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | — | Active Not Recruiting | — | — | — |
NCT03029403CT.gov Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
NCT06556108CT.gov ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors | — | Completed | — | — | — |
NCT03373708CT.gov Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer | — | Unknown | — | — | — |
NCT02224599CT.gov Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies | — | Terminated | — | — | — |
NCT02876510CT.gov ACTolog in Patients With Solid Cancers | — | Completed | — | — | — |
NCT02737475CT.gov An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread | — | Completed | — | — | — |
NCT02566304CT.gov Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | — | Completed | — | — | — |
NCT02574728CT.gov Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors | — | Active Not Recruiting | — | — | — |
NCT01554371CT.gov Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies | — | Completed | — | — | — |
NCT01067989CT.gov Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01046487CT.gov Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate | — | Completed | — | — | — |
NCT00578461CT.gov T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE | — | Terminated | — | — | — |
NCT00597519CT.gov A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy | — | Completed | — | — | — |
NCT00109031CT.gov Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE) | — | Completed | — | — | — |
NCT00525642CT.gov Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer | — | Unknown | — | — | — |
NCT00004230CT.gov Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation | — | Completed | — | — | — |
NCT00002854CT.gov High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | National Cancer Institute (NCI) | P3 | B · 63 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →